IgM antibodies identified by a DTT‐ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype*
Authors:
- 1 November 2001
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 15 (s6) , 28-35
Abstract
A positive crossmatch that is rendered negative by treating the serum with the IgM‐reducing agent dithiothreitol (DTT) is generally reported not to influence short‐term renal graft outcome. Its effect on long‐term (3 years) cadaveric and live‐donor transplant function, however, is less clear. We evaluated the effect of IgM antibodies in a DTT‐ameliorated positive crossmatch (DTT‐APXM) on long‐term renal graft outcome in 1290 consecutive cadaveric renal transplants (8‐year survival) and 384 live‐donor renal transplants (7‐year survival) from patients transplanted between 1990 and 1999. The data show that 1‐ and 8‐year graft survival for cadaveric renal transplants in patients with IgM antibodies (n=72) (DWFG censored=91% and 65%; DWFG not censored=90% and 60%) was not significantly different from the group without IgM antibodies (n=1218) (DWFG censored=92% and 71%; DWFG not censored=87% and 55%) (log‐rank=0.25 for DWFG censored, log‐rank=0.92 for DWFG not censored). The one‐ and seven‐year graft survival for live‐donor renal transplants in patients with IgM antibodies seen in a DTT‐APXM (n=22) (DWFG censored=95% and 83%; DWFG not censored=95% and 66%) was not significantly different from the group without IgM antibodies (n=362) (DWFG censored=94% and 81%; DWFG not censored=92% and 73%) (log‐rank=0.61 for DWFG censored, log‐rank=0.89 for DWFG not censored). DR phenotype was found to be associated with the strong (>40% cell death) IgM reactivity in both black and white patients. In white patients, DR2 was more frequently seen with a strong IgM crossmatch (48.2%) than in molecularly typed controls (28.5%) (PPP=0.07) and concomitant with that DR6 increase, DR5 was decreased in frequency in black patients (7.6%) compared with controls (41%) (P<0.03). These data show that long‐term graft survival in renal transplantation is not negatively influenced by the presence of donor‐reactive lymphocytotoxic antibodies in the crossmatch ameliorated by serum DTT treatment. They also suggest that the strength of the IgM antibody response is regulated in part by certain gene (s) of the DR region.Keywords
This publication has 17 references indexed in Scilit:
- GRAFT-PROTECTIVE ROLE OF HIGH PRETRANSPLANTATION IgA-ANTI-FAB AUTOANTIBODIESTransplantation, 2000
- FLOW CYTOMETRY-DETECTED IgG IS NOT A CONTRAINDICATION TO RENAL TRANSPLANTATIONTransplantation, 1999
- Presentation of the Goodpasture Autoantigen to CD4 T Cells Is Influenced More by Processing Constraints Than by HLA Class II Peptide Binding PreferencesJournal of Biological Chemistry, 1998
- HLA-DR AND DQ TYPING BY POLYMERASE CHAIN REACTION USING SEQUENCE-SPECIFIC PRIMER MIXES REDUCES THE INCIDENCE OF PHENOTYPIC HOMOZYGOSITY (BLANKS) OVER SEROLOGY1Transplantation, 1996
- Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor‐α by HLA‐DR2+ T cellsAnnals of Neurology, 1995
- IgG ANTIBODIES AGAINST AN HLA ANTIGEN ARE ASSOCIATED WITH ACTIVATED CYTOTOXIC T CELLS AGAINST THIS ANTIGEN, IgM ARE NOTTransplantation, 1994
- AHG AND DTE/AHG PROCEDURE IDENTIFICATION OF CROSSMATCH-APPROPRIATE DONOR-RECIPIENT PAIRINGS THAT RESULT IN IMPROVED GRAFT SURVIVALTransplantation, 1991
- SUCCESSFUL RENAL ALLOGRAFTS IN RECIPIENTS WITH CROSSMATCH-POSITIVE, DITHIOERYTHRITOL-TREATED NEGATIVE SERATransplantation, 1989
- IMMUNOGLOBULIN CLASS AND SPECIFICITY OF ANTIBODIES CAUSING POSITIVE T CELL CROSSMATCHESTransplantation, 1986
- Evaluation of dithiothreitol (DTT) for inactivation of IgM antibodies.Journal of Clinical Pathology, 1978